These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 1109800

  • 1. Lymphatic obstruction in carcinomatous ascites.
    Feldman GB.
    Cancer Res; 1975 Feb; 35(2):325-32. PubMed ID: 1109800
    [Abstract] [Full Text] [Related]

  • 2. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation.
    Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF.
    Cancer Res; 1993 Jun 01; 53(11):2631-43. PubMed ID: 8495427
    [Abstract] [Full Text] [Related]

  • 3. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity.
    Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF.
    Cancer Res; 1995 Jan 15; 55(2):369-75. PubMed ID: 7812970
    [Abstract] [Full Text] [Related]

  • 4. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.
    Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF.
    Cancer Res; 1995 Jan 15; 55(2):360-8. PubMed ID: 7812969
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.
    Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF.
    Cancer Res; 1995 Jan 15; 55(2):376-85. PubMed ID: 7529135
    [Abstract] [Full Text] [Related]

  • 6. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma.
    Feldman GB, Knapp RC, Order SE, Hellman S.
    Cancer Res; 1972 Aug 15; 32(8):1663-6. PubMed ID: 5044130
    [No Abstract] [Full Text] [Related]

  • 7. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL.
    Clin Cancer Res; 2006 Mar 15; 12(6):1928-35. PubMed ID: 16551879
    [Abstract] [Full Text] [Related]

  • 8. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.
    Greenbaum LM, Grebow P, Johnston M, Prakash A, Semente G.
    Cancer Res; 1975 Mar 15; 35(3):706-10. PubMed ID: 46779
    [Abstract] [Full Text] [Related]

  • 9. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
    Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A.
    J Clin Invest; 1990 Sep 15; 86(3):851-5. PubMed ID: 2394835
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tumoricidal effects of sodium hexachloroiridate on an ascitic tumor in mice.
    Kolodny GM, Rose C.
    Cancer Res; 1983 Jul 15; 43(7):3101-3. PubMed ID: 6682698
    [Abstract] [Full Text] [Related]

  • 12. Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model.
    Feki A, Berardi P, Bellingan G, Major A, Krause KH, Petignat P, Zehra R, Pervaiz S, Irminger-Finger I.
    Crit Rev Oncol Hematol; 2009 Oct 15; 72(1):1-9. PubMed ID: 19179094
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.
    Oncol Rep; 2003 Oct 15; 10(1):89-95. PubMed ID: 12469150
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lymphatic drainage of the peritoneal cavity in experimental ascites.
    Szabó G, Magyar Z, Serényi P.
    Acta Med Acad Sci Hung; 1975 Oct 15; 32(3-4):337-48. PubMed ID: 1235450
    [Abstract] [Full Text] [Related]

  • 17. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
    Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE.
    J Immunol; 1999 Dec 15; 163(12):6378-85. PubMed ID: 10586027
    [Abstract] [Full Text] [Related]

  • 18. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
    Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H.
    Anticancer Res; 2000 Dec 15; 20(1A):155-60. PubMed ID: 10769648
    [Abstract] [Full Text] [Related]

  • 19. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats.
    Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, Bleichrodt RP.
    Eur J Surg Oncol; 2001 Jun 15; 27(4):359-63. PubMed ID: 11417980
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
    Hirte HW, Miller D, Tonkin K, Findlay B, Capstick V, Murphy J, Buckman R, Carmichael J, Levine M, Hill W.
    Gynecol Oncol; 1997 Jan 15; 64(1):80-7. PubMed ID: 8995552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.